Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study

Hepatology(2021)10.1002/hep.32053Source: DataRank Database

A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study is a research paper published in Hepatology (2021). On theSindex it has a DataRank of 0.483. It has been cited 12 times, with 8 citing works in its 1-hop citation network.

N/A

0.483DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access12 citations · 8 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02786537

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.87)OA: hybridTopics (116)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 80%Citation Network 20%

Base Score Contribution

0.385

From this paper's citation signal

Citation Network Contribution

0.0978

From 4 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 8 citers.

Hepatitis C Virus: Insights Into Its History, Treatment, Challenges, and Future Directions
Cureus202321 citations42 referencesContributes 0.074
Multiple functions of heterogeneous nuclear ribonucleoproteins in the positive single-stranded RNA virus life cycle
Frontiers in Immunology202248 citations168 referencesContributes 0.023
Clinical trials reimagined
Hepatology20234 citations104 referencesContributes 0.015
Revolutionizing HCV Therapy: microRNA Approaches in New Era of Treatment
IntechOpen eBooks20241 citations245 referencesContributes 0.003
A 10-Year Retrospective Cohort Study of Real-World Effectiveness of Sofosbuvir-Based Regimens for Hepatitis C in a Single Center in China
Infectious Microbes & Diseases20230 citations31 referencesContributes 0.000

Authors (28)

Juhi Moon,Kenneth E. Sherman ORCID,Giuseppe Morelli,Jama M. Darling,Andrew J. Muir ORCID

Live enrichment

PubMed:34255381 PMC:PMC8639765 OpenAlex:https://openalex.org/W3177821447

NIAAA NIH HHS

Grant: K24 AA022523

NIDA NIH HHS

Grant: K24 DA034621

NCATS NIH HHS

Grant: UL1 TR001409

Patient-Centered Outcomes Research Institute

Grant: HPC‐1503‐27891

National Institutes of Health

Grant: 5K24AA022523-10

Mentoring Multidisciplinary Patient-Oriented Research in Liver Disease

National Institutes of Health

Grant: 5K24DA034621-10

Midcareer Investigator Award in Patient-Oriented Research (Parent K24)

Merck

AbbVie

FWCI

0.87

Citation Percentile

0.7%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc

journalhttps://doi.org/10.1002/hep.32053

publisherhttps://doi.org/10.1002/hep.32053

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.32053

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/hep.32053

publisherhttps://journals.lww.com/10.1002/hep.32053

Fields of Study

Hepatitis C virus researchHepatitis Viruses Studies and EpidemiologyHepatitis B Virus Studies0301 basic medicine03 medical and health sciences0302 clinical medicine2-NaphthylamineAdministration, OralAdolescentAdultAgedAged, 80 and overAnilidesAntiviral AgentsBenzimidazolesBenzofuransCyclopropanesDrug CombinationsDrug Therapy, CombinationFemaleFluorenesFollow-Up StudiesGenotyping TechniquesHepacivirusHepatitis C, ChronicHumansImidazolesLactams, MacrocyclicMaleMiddle AgedProlineQuinoxalinesRNA, ViralRibavirinSofosbuvirSulfonamidesSustained Virologic ResponseTreatment OutcomeUracilValineYoung Adult

MeSH Terms

SofosbuvirSustained Virologic ResponseAdministration, OralAdolescentAdultAgedAged, 80 and overAnilidesAntiviral AgentsBenzimidazolesBenzofuransCyclopropanesDrug CombinationsDrug Therapy, CombinationFemaleFluorenesFollow-Up StudiesHumansImidazolesMaleMiddle AgedProlineQuinoxalinesRibavirinRNA, ViralSulfonamidesUracilValine2-NaphthylamineHepacivirusTreatment OutcomeHepatitis C, ChronicLactams, MacrocyclicYoung AdultGenotyping Techniques

Keywords

MedicineOmbitasvirParitaprevirSofosbuvirRandomized controlled trialRibavirinDasabuvirAdverse effectInternal medicineSimeprevirLedipasvirRitonavirTolerabilityHepatitis CHepatitis C virusViral loadVirologyAdultCyclopropanesAdolescentGenotyping TechniquesAdministration, OralHepacivirusAntiviral AgentsArticle2-NaphthylamineHealth SciencesHumansAnilidesAgedBenzofuransAged, 80 and overFluorenesHepatitis C, ChronicDrug CombinationsInternal Medicine and SpecialtiesBenzimidazolesDrug Therapy, CombinationFemaleFollow-Up Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 16: 16. Peace & justiceSDG 0: Good health and well-being